These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 25666151

  • 1. Moxifloxacin pharmacokinetic profile and efficacy evaluation in empiric treatment of community-acquired pneumonia.
    Öbrink-Hansen K, Hardlei TF, Brock B, Jensen-Fangel S, Kragh Thomsen M, Petersen E, Kreilgaard M.
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2398-404. PubMed ID: 25666151
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis.
    Yoshida K, Okimoto N, Kishimoto M, Fukano H, Hara H, Yoneyama H, Moriya O, Kawanishi M, Kimura M, Matsushima T, Niki Y.
    J Infect Chemother; 2011 Oct; 17(5):678-85. PubMed ID: 21847518
    [Abstract] [Full Text] [Related]

  • 3. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections.
    Van Wart S, Phillips L, Ludwig EA, Russo R, Gajjar DA, Bello A, Ambrose PG, Costanzo C, Grasela TH, Echols R, Grasela DM.
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4766-77. PubMed ID: 15561855
    [Abstract] [Full Text] [Related]

  • 4. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.
    Stass H, Dalhoff A.
    Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709
    [Abstract] [Full Text] [Related]

  • 5. Population pharmacokinetics and pharmacodynamic evaluation of intravenous and enteral moxifloxacin in surgical intensive care unit patients.
    Kees MG, Schaeftlein A, Haeberle HA, Kees F, Kloft C, Heininger A.
    J Antimicrob Chemother; 2013 Jun; 68(6):1331-7. PubMed ID: 23463212
    [Abstract] [Full Text] [Related]

  • 6. Proposed Pharmacokinetic-Pharmacodynamic Breakpoint of Garenoxacin and Other Quinolones.
    Yamagishi Y, Shibata T, Nakagawa S, Nomura N, Mitsuyama J, Mikamo H.
    Jpn J Infect Dis; 2017 Nov 22; 70(6):616-620. PubMed ID: 28890509
    [Abstract] [Full Text] [Related]

  • 7. Pharmacodynamic analysis of the microbiological efficacy of telithromycin in patients with community-acquired pneumonia.
    Shi J, Pfister M, Jenkins SG, Chapel S, Barrett JS, Port RE, Howard D.
    Clin Pharmacokinet; 2005 Nov 22; 44(3):317-29. PubMed ID: 15762772
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetic and pharmacodynamic aspects of oral moxifloxacin 400 mg/day in elderly patients with acute exacerbation of chronic bronchitis.
    Pea F, Pavan F, Lugatti E, Dolcet F, Talmassons G, Screm MC, Furlanut M.
    Clin Pharmacokinet; 2006 Nov 22; 45(3):287-95. PubMed ID: 16509760
    [Abstract] [Full Text] [Related]

  • 9. A Monte Carlo pharmacokinetic/pharmacodynamic simulation to evaluate the efficacy of minocycline, tigecycline, moxifloxacin, and levofloxacin in the treatment of hospital-acquired pneumonia caused by Stenotrophomonas maltophilia.
    Wei C, Ni W, Cai X, Cui J.
    Infect Dis (Lond); 2015 Nov 22; 47(12):846-51. PubMed ID: 26167850
    [Abstract] [Full Text] [Related]

  • 10. Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis.
    Noreddin AM, Reese AA, Ostroski M, Hoban DJ, Zhanel GG.
    Clin Ther; 2007 Dec 22; 29(12):2685-9. PubMed ID: 18201584
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): Data from the Delafloxacin Phase 3 CABP Trial.
    McCurdy S, Nenninger A, Sheets A, Keedy K, Lawrence L, Quintas M, Cammarata S.
    Int J Infect Dis; 2020 Aug 22; 97():374-379. PubMed ID: 32534142
    [Abstract] [Full Text] [Related]

  • 12. Impact of poor compliance with levofloxacin and moxifloxacin on respiratory tract infection antimicrobial efficacy: a pharmacokinetic/pharmacodynamic simulation study.
    Carral N, Lukas JC, Oteo I, Suarez E.
    Int J Antimicrob Agents; 2015 Jan 22; 45(1):79-83. PubMed ID: 25450804
    [Abstract] [Full Text] [Related]

  • 13. A Pharmacokinetic and Pharmacodynamic Study on Intravenous Cefazedone Sodium in Patients with Community-acquired Pneumonia.
    Gao L, Zhu Y, Lyu Y, Hao FL, Zhang P, Wei MJ.
    Chin Med J (Engl); 2015 May 05; 128(9):1160-4. PubMed ID: 25947397
    [Abstract] [Full Text] [Related]

  • 14. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics.
    Nightingale CH.
    Pharmacotherapy; 2000 Mar 05; 20(3):245-56. PubMed ID: 10730681
    [Abstract] [Full Text] [Related]

  • 15. Clinical dose findings of sitafloxacin treatment: pharmacokinetic-pharmacodynamic analysis of two clinical trial results for community-acquired respiratory tract infections.
    Kohno S, Niki Y, Kadota J, Yanagihara K, Kaku M, Watanabe A, Aoki N, Hori S, Fujita J, Tanigawara Y.
    J Infect Chemother; 2013 Jun 05; 19(3):486-94. PubMed ID: 23525983
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in the UK during 2002/3 determined locally and centrally by BSAC methods.
    Morrissey I, Robbins M, Viljoen L, Brown DF.
    J Antimicrob Chemother; 2005 Feb 05; 55(2):200-8. PubMed ID: 15649996
    [Abstract] [Full Text] [Related]

  • 19. A Prospective Study of the Efficacy, Safety and Pharmacokinetics of Enteral Moxifloxacin in the Treatment of Hemodialysis Patients with Pneumonia.
    Tokimatsu I, Shigemura K, Kotaki T, Yoshikawa H, Yamamichi F, Tomo T, Arakawa S, Fujisawa M, Kadota JI.
    Intern Med; 2017 Feb 05; 56(11):1315-1319. PubMed ID: 28566592
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.